Leukocytes recruited to regions of focal cerebral ischemia may contribute to tissue injury by their ability to promote inflammation. A novel group of drugs, the 21-aminosteroids, have been observed to reduce neurologic damage and vasogenic cerebral edema in animal models of stroke by inhibiting lipid peroxidation. Production of hydrogen peroxide and free radicals by leukocytes during the inflammatory response may contribute to lipid peroxidation and other consequences of free radical-mediated tissue injury. We assessed the effect of U74500A, a 21-aminosteroid, on the generation of hydrogen peroxide by and on the chemiluminescence of stimulated polymorphonuclear leukocytes and monocytes from normal humans. Received March 22, 1990; accepted May 23, 1990. ate large quantities of hydrogen peroxide and oxygen free radical species, which may contribute to postischemic injury in focal cerebral ischemia by a variety of mechanisms. 6 Inhibitory effects on leukocytes' generation of hydrogen peroxide and free radicals might give further insight regarding how 21-aminosteroids are beneficial in focal cerebral ischemia and other conditions. Therefore, we assessed the ability of a 21-aminosteroid, U74500A, to inhibit the generation of hydrogen peroxide by and the chemiluminescence of stimulated human polymorphonuclear leukocytes and monocytes.
T he 21-aminosteroids, a new group of compounds derived from glucocorticoids, lack glucocorticoid and mineralocorticoid activities. 1 The 21-aminosteroids have been shown to be potent inhibitors of membrane lipid peroxidation because of their abilities to scavenge lipid peroxyl radicals and inhibit iron-dependent lipid peroxidation, although other mechanisms have been suggested. 2 The 21-aminosteroids have been observed to improve survival, preserve neurons, and reduce cerebral edema in animal models of focal cerebral ischemia, presumably related to effects on lipid peroxidation. 3 ' 4 Leukocytes, predominantly polymorphonuclear leukocytes, are recruited to areas of focal cerebral ischemia shortly after it occurs, whereas monocytes migrate more slowly. 5 Stimulated leukocytes gener-ate large quantities of hydrogen peroxide and oxygen free radical species, which may contribute to postischemic injury in focal cerebral ischemia by a variety of mechanisms. 6 Inhibitory effects on leukocytes' generation of hydrogen peroxide and free radicals might give further insight regarding how 21-aminosteroids are beneficial in focal cerebral ischemia and other conditions. Therefore, we assessed the ability of a 21-aminosteroid, U74500A, to inhibit the generation of hydrogen peroxide by and the chemiluminescence of stimulated human polymorphonuclear leukocytes and monocytes.
Subjects and Methods
Blood samples were drawn from 12 normal healthy volunteers who had signed a consent form approved by our institutional review board. Samples from six volunteers were used for the polymorphonuclear leukocyte experiments, and samples from the other six volunteers were used for the monocyte experiments. Two separate groups were used because of the large volume of blood required for each study. The six volunteers for the polymorphonuclear leukocyte experiments ranged in age from 26 to 49 (mean 36) years; four were women and the other two were men. The six volunteers for the monocyte experiment were aged 22-54 (mean 39) years; two were women and the other four were men. No volunteer had any known disease, and each volunteer had abstained from all medications for at least 7 days.
Polymorphonuclear leukocytes were prepared by dextran sedimentation as previously described.
7 Polymorphonuclear leukocytes were 86% pure (6% lymphocytes, 8% monocytes) as determined by WrightGiesma staining, and average viability was 97%.
Monocytes were harvested by drawing 150 ml whole blood into a series of 7-ml evacuated glass tubes containing 0.07 ml of a 15% potassium ethylenediaminetetraacetic acid solution (10.5 mg/ml; Becton Dickinson, Rutherford, N.J.) and mixing gently. All cell isolation techniques were carried out at room temperature unless otherwise noted. Twenty-five milliliters whole blood was mixed with an equal volume of Sepracell solution (Sepratech Corp., Oklahoma City, Okla.) and centrifuged for 20 minutes at l,500g. The top 10-ml layer containing platelets and mononuclear cells was removed, pooled with a second identical preparation, and resuspended in 30 ml phosphate-buffered saline. The suspension was centrifuged for 10 minutes at 300g, resuspended in 15 ml phosphate-buffered saline, mixed with 22.5 ml a^cn suiuuuu anu >^ntii!ugccl tor Z\i minutes at l,500g. The top 10-ml layer containing monocytes and platelets was removed, pooled with a second identical preparation, resuspended in 30 ml phosphate-buffered saline, and centrifuged for 10 minutes at 300g. The monocyte pellet was resuspended in 7.5 ml phosphate-buffered saline and placed on a 12-16% sucrose gradient. The pellet was centrifuged for 12 minutes at 250g to remove contaminating platelets. The monocyte pellet was washed twice in phenol red working solution 8 (buffer) containing 120 mM NaCl, 9 mM dextrose, 11 mM sodium citrate, 11 mM Tris, 1 mM KH 2 PO 4 , 3 mM KC1, and 1 mM MgCl 2 (Sigma Chemical Co., St. Louis), pH 7.35, for the hydrogen peroxide assay. For the chemiluminescence assay, a modified Tyrode's solution was used as the buffer. Harvested monocytes averaged 78% pure (22% lymphocytes) as determined by nonspecific a-napthyl butyrate esterase staining.
9 Cell viability, determined by mixing 0.1 ml monocytes with 0.1 ml of 0.2% trypan blue in phosphate-buffered saline and assessing the percentage of cells excluding the dye, averaged 96% for all preparations.
Both polymorphonuclear leukocytes and monocytes were incubated with various concentrations of U74500A (The Upjohn Co., Kalamazoo, Mich.) for 20 minutes at room temperature before assay. The drug was diluted to the appropriate concentrations in 0.1% ethanol in 0.9% saline just before use. The concentration of U74500A used depended on the type of cell and the assay performed. For the assay of hydrogen peroxide generation we used 0,1, 5, and 10 fiM U74500A, and for the assay of chemiluminescence we used 0 and 100 fiM U74500A. All samples were run in duplicate, and the values reported are the average of the two results for each assay.
Polymorphonuclear leukocytes and monocytes were assayed for hydrogen peroxide generation using a modification of the colorimetric method of Pick and Keisari.
8 Preincubated 1.0-ml samples of polymorphonuclear leukocytes (3.95 x 10 6 cells/ml) or monocytes (1.41 xlO 6 cells/ml) were stimulated by the addition of 0.1 ml of 0.22 fiM phorbol myristate acetate (Sigma). Cells were allowed to react for 30 minutes at 37° C in a shaking water bath. The reaction was stopped by spinning samples in a refrigerated centrifuge (4° C) at 2,000g for 10 minutes and decanting the supernatant. Samples were brought to room temperature by placing them in a 22° C water bath for 30 minutes, at which time pH was adjusted to 12.5 by the addition of 10 /tl IN NaOH. Standards were subjected to identical conditions. Samples were run on a Shimadzu 160A spectrophotometer (Columbia, Md.) at an absorption wavelength of 610 nm to measure horseradish peroxidase-mediated oxidation of phenol red by hydrogen peroxide. Results are expressed as nanomoles of hydrogen peroxide generated by 10 6 cells in 30 minutes.
Chemiluminescence was measured in a Beckman Model LS 1801 ambient temperature liquid scintillation counter (Fullerton, Calif.). Measurements were carried out in plastic scintillation vials in the dark with exposure limited to red light. Data were collected using the single-photon monitor feature of the instrument, in which the coincidence circuit is not used. The counts represent an average of the total number of events seen by each photomultiplier tube during the counting period. For the polymorphonuclear leukocyte studies, 2.0 ml of modified Tyrode's solution (37° C) without luminol and 0.5 ml of preincubated polymorphonuclear leukocyte suspension (1 x 10 7 cells/ml) was added to each vial. Polymorphonuclear leukocytes were activated by the addition of 0.025 ml latex particles (7.9xlO 9 particles/ml, 10.995 /L t m in diameter; Sigma), and the reaction was monitored for 5 minutes. For the monocyte studies, 2.0 ml of modified Tyrode's solution (37° C) containing 2.3 x 10" 8 M luminol (Sigma) and 1.0 ml preincubated monocyte suspension (lxlO 6 cells/ml) was added to each vial. Monocytes were activated by the addition of 0.05 ml latex particles, and the reaction was monitored for 5 minutes. For both cell types, blanks were run under identical conditions but without latex activation. Results are expressed as counts per 10 3 cells in 5 minutes.
The differences in dose effects for each subject were compared. Therefore, a within-subjects analysis of variance was conducted for the polymorphonuclear leukocyte and monocyte data for each measure of free radical production to determine if there were overall significant differences among the concentrations of U74500A used. Post hoc analyses (Duncan's test), adjusted in regard to the within-subject design for multiple comparisons, were performed to determine which drug concentrations differed significantly from the vehicle (0 ^.m concentration) and from each other. Probability values of <0.05 were considered to indicate significant differences.
Results
U74500A markedly affected hydrogen peroxide generation associated with stimulated polymorphonuclear leukocytes (F 4i20 =38.76,/><0.001) ( Table 1) . The 5 fiM concentration inhibited hydrogen peroxide generation significantly more (/?<0.001) than the 1 fiM concentration, and the 10 fiM concentration was significantly more effective (p<0.05) than the 5 fiM concentration; these observations support a doseresponse relation. Similarly, hydrogen peroxide generation associated with stimulated monocytes was also significantly affected by U74500A (F 315 =9.85, p<0.01). There was a significantly greater effect with the 5 and 10 fiM concentrations than with the 1 fim concentration (/?<0.001), but the first two concentrations did not differ from each other. A known amount of hydrogen peroxide (10 fiM) mixed with 10 /xM U74500A and no leukocytes yielded the same results as that concentration of hydrogen peroxide mixed with the buffer alone. This observation demonstrates that U74500A does not scavenge hydrogen peroxide and suggests that the drug inhibits hydrogen peroxide generation by stimulated leukocytes.
Chemiluminescence of polymorphonuclear leukocytes was not significantly affected by U74500A ( Table  2) . Chemiluminescence of stimulated monocytes was significantly reduced by U74500A (F U =6.55,/J=0.05); the effect of 100 /iM U74500A differed significantly from that of 0 fiM U74500A (p<0.05). Lower concen- •p<0.05 different from 0 /im by within-subjects analysis of trations of U74500A could not be assessed because of the limited supply of monocytes. Discussion Our results indicate that U74500A markedly affects the generation of hydrogen peroxide by stimulated human polymorphonuclear leukocytes and monocytes. This inhibition occurred in a dose-dependent manner for both cell types, with the maximal effect occurring between 1 and 5 /tM U74500A. The drug appears to reduce hydrogen peroxide generation by inhibiting production, not by scavenging, because U74500A mixed with a known quantity of hydrogen peroxide did not lower the amount of hydrogen peroxide that could be measured. Chemiluminescence measures the production of photons in the visible spectrum, which accompanies the respiratory burst of inflammatory cells (polymorphonuclear leukocytes and monocytes), closely correlating with the generation of oxygen free radical species such as superoxide, hydrogen peroxide, singlet oxygen, and the hydroxyl radical. This more general marker of oxygen free radical species was reduced by U74500A only in stimulated monocytes. It appears that this drug has potent inhibitory effects on the generation of hydrogen peroxide by inflammatory leukocytes, and it may have broader effects on the production of oxygen free radicals, at least in monocytes, as indicated by the reduction in monocyteassociated chemiluminescence.
Hydrogen peroxide and other oxygen free radical species are highly toxic compounds capable of causing cellular tissue injury. 6 Free radicals are generated in areas of incomplete ischemia or during reperfusion by several biochemical reactions and by inflammatory leukocytes (polymorphonuclear leukocytes and monocytes). Leukocytes are observed within areas of focal cerebral ischemia within a few hours after onset. 10 Reducing the number of circulating leukocytes before the induction of experimental ischemic stroke by pretreating with chemotherapy has been shown to ameliorate the physiologic effects of focal ischemia.
11 Its ability to markedly reduce leukocyteassociated hydrogen peroxide generation may in part explain how U74500A reduces the consequences of experimental focal cerebral ischemia. This compound interferes with the ability of leukocytes to generate hydrogen peroxide and may therefore impede a wide variety of the cellular consequences induced by oxygen free radical species and their derivatives.
Reduced concentrations of leukocyte-associated oxygen free radicals caused by 21-aminosteroids, which we have demonstrated, may have other favorable effects. For example, atherosclerosis, the process underlying many human ischemic strokes, appears to be closely associated with free radical modification of low density lipoprotein (LDL)-cholesterol by monocytes/macrophages and other cells. 12 Oxidatively modified LDL-cholesterol is avidly taken up by foam cells, and LDL-cholesterol has other effects within plaque that can enhance the progression of atherosclerosis. Compounds with antioxidant effects appear to impede experimental atherogenesis, and 21-aminosteroids should be evaluated for similar effects. 13 The 21-aminosteroids have been effectively employed in animal models of head and spinal cord trauma, subarachnoid hemorrhage, and global ischemia.
14 The potential role of leukocytes in these disorders is less clear than it is in focal ischemia, but our observations may be relevant in these disorders as well. In most experiments the 21-aminosteroid U74006F, the structure of which differs only slightly from that of U74500A, has been used.
14 Although both 21-aminosteroids have been effectively employed in animal models of focal cerebral ischemia, U74500A more effectively inhibits iron-dependent lipid peroxidation. 15 Glucocorticoids have been widely employed with varying success in a variety of ischemic and traumatic central nervous system disorders. Because of their inhibitory effects on leukocytes and their relative lack of side effects, the 21-aminosteroids need further evaluation, both preclinically and in clinical trials of treatment for these conditions.
